With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild

With the Nov. 5 FDA approval of Genvoya, a Stribild follow-on using tenofovir alafenamide (TAF) in place of Viread (tenofovir disoproxil fumarate), Gilead Sciences Inc. is pricing the new drug on par with its predecessor, leaving it to make a commercial case based on safety advantages.

Gilead told "The Pink Sheet" DAILY that Genvoya (elvitegravir/cobicistat/emtricitabine/TAF) will have a wholesale acquisition cost of $31,362, which it says is at parity with Stribild, the "quad" pill launched in 2012 Also see "The New Quad: FDA Approves Gilead’s